Interview with Juan Craveri, President and CEO, Craveri
Craveri has one of the most distinguished histories of any of the Argentine pharmaceutical companies, with over 120 years of history. Three generations after it’s foundation, do you feel you…
Address: Arengreen 830 (C1405CYH), Buenos Aires,Argentina
Tel: +54 11 5453-4555
Web: http://www.craveri.com.ar/
One of the oldest pharmaceutical companies in Argentina, Craveri is a family-run company which is one of the forerunners in repositioning itself in order to best face the challenges of the pharmaceutical industry in the 21st century. Since 1996, the company has been involved with bioengineering, and was the first company in Argentina to help develop skin replacement treatments. Combined with their more traditional products, Craveri is well-positioned for growth and success in the years to come.
Diabetology, Phlebology, Neurology, Cardiovascular Disorders, Gastroenterology and Obesity
Craveri has one of the most distinguished histories of any of the Argentine pharmaceutical companies, with over 120 years of history. Three generations after it’s foundation, do you feel you…
Argentina’s pharmaceutical industry combines a robust domestic manufacturing base with growing international reach and regulatory credibility. In this interview, Mauricio Claverí, Chief Economist at CILFA, explores how local companies are…
Juan Jose Marconi, Executive Director of Cooperala, offers a unique perspective shaped by decades of leadership across Argentina’s pharmaceutical and healthcare sectors. With a strong academic background in applied mathematics,…
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
A roundup of some of the biggest stories coming out of Latin American pharma and healthcare, including Mexico’s move to speed up the drug review process; Sanfer’s acquisition of Columbia’s…
A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4…
An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s…
A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
See our Cookie Privacy Policy Here
